In this short piece I’ll step into the signatory seat and explain what risk assessment actually looks like when I review a job bag: not a sterile tick-box exercise, but a live weighing of audience, context, evidence and consequence. TL;DR:…
I review 100’s of clinician videos and often i think: technically great, strategically risky. In CASE/0360/11/24 (Complainant v AstraZeneca) a Trixeo video on the company website looked harmless until the PMCPA sliced it apart. I’ll take you through what went…
I read the PMCPA Social Media Guidance 2026 with a notebook and a headache. As an ABPI Final Signatory and industry mentor I’m writing this not to frighten you, but to hand you a pragmatic playbook. Regulators (MHRA, ABPI, PMCPA)…
Vifor’s corporate website displayed inverted triangle symbols in blue/grey/white (not black) on IV iron product pages and mixed public and HCP information without separation. The site was deactivated and brand information removed.
AstraZeneca admitted an employee re-tweeted positive clinical-trial-related posts about Forxiga and a Lynparza news tweet from a personal account. The Panel found promotion of unlicensed indications, advertising POMs to the public, and lack of certification.
Bristol-Myers Squibb admitted a promotional article misquoted 30‑month overall survival figures for intermediate/poor-risk aRCC by using ITT data. The online article was removed and a corrected reprint with apology was issued.
